Uncategorized
Clearside reports BCVA gain in phase 12 trial of suprachoroidal injection of triamcinolone acetonide
Patients with noninfectious uveitis experienced an improvement in best corrected visual acuity in a phase 1/2 clinical trial involving a suprachoroidal injection of triamcinolone acetonide, Clearside Biomedical reported in a press release.The trial included eight patients who received a single suprachoroidal injection of triamcinolone acetonide with Clearside's proprietary microinjector.